Article
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.
Clinical lymphoma, myeloma & leukemia - 1 Apr 2022
Ambinder Alexander, Smith Matthew, Tsai Hua-Ling, Varadhan Ravi, DeZern Amy, Dalton William, Gocke Christian, Webster Jonathan, Gondek Lukasz, Gojo Ivana, Ali Syed Abbas, Huff Carol Ann, Swinnen Lode, Wagner-Johnston Nina, Showel Margaret, Prince Gabrielle, Borrello Ivan, Bolaños-Meade Javier, Luznik Leo, Jain Tania, Imus Philip, Fuchs Ephraim, Ambinder Richard, Gladstone Douglas E, Levis Mark, Jones Richard, Ghiaur Gabriel, Smith B Douglas
Abstract excerpt
INTRODUCTION: Mutations in the IDH1 or IDH2 genes are detected in approximately 20% of cases of acute myeloid leukemia (AML). Few studies have examined the impact of IDH mutations in AML on allogeneic bone marrow transplant (alloBMT) outcomes. PATIENTS AND METHODS: In this single center study, alloBMT outcomes for 61 patients with IDH-mutated (mIDH) AML were compared to those for 146 patients with IDH-wildtype...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.